A Study to Compare the Efficacy of Rivaroxaban, Warfarin and LMWH for the Treatment of VTE in Newly Diagnosed Cancer Patients
Latest Information Update: 19 Jan 2017
Price :
$35 *
At a glance
- Drugs Rivaroxaban (Primary) ; Low molecular weight heparins; Warfarin
- Indications Venous thromboembolism
- Focus Therapeutic Use
- 06 Dec 2016 Results comparing the risk of major bleeding presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
- 14 Jul 2016 New trial record
- 07 Jun 2016 Results assessing association between the duration of anticoagulation and VTE recurrence (n=1158) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology